Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|11|4|317-323

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.11, Iss.4, 2016-10, pp. : 317-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2603-2611

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3636-3643

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

By  

Urologia Internationalis, Vol. 88, Iss. 1, 2011-12 ,pp. : 25-33

Karger

Access to resources Recommend Favorite

Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy

By  

Urologia Internationalis, Vol. 75, Iss. 1, 2005-07 ,pp. : 43-49

Karger

Access to resources Recommend Favorite